24 results on '"Pocali, B."'
Search Results
2. Vincristine as treatment for recurrent episodes of thrombotic thrombocytopenic purpura
- Author
-
Ferrara, F., Annunziata, M., Pollio, F., Palmieri, S., Copia, C., Mele, G., Pocali, B., and Schiavone, E.
- Published
- 2002
- Full Text
- View/download PDF
3. Rituximab: a useful drug for a repeatedly relapsed hairy cell leukemia patient
- Author
-
Pollio, F., Pocali, B., Palmieri, S., Morabito, P., Scalia, G., Del Vecchio, L., and Ferrara, F.
- Published
- 2002
- Full Text
- View/download PDF
4. Vinorelbine and cyclophosphamide plus G-CSF as mobilisation regimen for patients with multiple myeloma
- Author
-
Palmieri, S., Pocali, B., Copia, C., Schiavone, E. M., Annunziata, M., Viola, A., and Ferrara, F.
- Published
- 2004
5. Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia
- Author
-
SCHIAVONE EM, DE SIMONE M, PALMIERI S, ANNUNZIATA M, POCALI B, COPIA C, D'AMICO MR, FERRARA F., DEL VECCHIO, LUIGI, Schiavone, Em, DE SIMONE, M, Palmieri, S, Annunziata, M, Pocali, B, Copia, C, D'Amico, Mr, DEL VECCHIO, Luigi, and Ferrara, F.
- Published
- 2003
6. Prevalence of hepatitis C virus antibodies in patients with monoclonal gammopathy
- Author
-
GUASTAFIERRO, Salvatore, Guariglia R, D’Amico MR, Capobianco G, Sagristani M, Pocali B, Tirelli A., Guastafierro, Salvatore, Guariglia, R, D’Amico, Mr, Capobianco, G, Sagristani, M, Pocali, B, and Tirelli, A.
- Published
- 2001
7. Vincristine as treatment for recurrent episodes of thrombotic thrombocytopenic purpura
- Author
-
Ferrara, F., primary, Annunziata, M., additional, Pollio, F., additional, Palmieri, S., additional, Copia, C., additional, Mele, G., additional, Pocali, B., additional, and Schiavone, E., additional
- Published
- 2001
- Full Text
- View/download PDF
8. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
- Author
-
Tobias Herold, Martin Andres, Gimena Dos Santos, Livio Trentin, Monia Marchetti, Antonio Cuneo, Robin Foà, Vladimir Strugov, Sunil Iyengar, Ozren Jakšić, Mark-David Levin, Angela Ferrari, Francesca Romana Mauro, Candida Vitale, Martin Spacek, Olga Kalashnikova, Eugene Nikitin, Ann Janssens, Constantine S. Tam, Julio Delgado, Maria Papaioannou, Barbara Pocali, Davide Rossi, Marina Motta, Niki Stavroyianni, Myriam Foglietta, Alicia Enrico, Carolina Cuéllar-García, Lara Malerba, Mónica Baile, Lydia Scarfò, Ellen van der Spek, Paolo Sportoletti, Maria Rosaria De Paolis, Mihnea Zdrenghea, Macarena Ortiz Pareja, Annalisa Chiarenza, Sabina Kersting, Fatima Miras, Yair Herishanu, Emili Montserrat, Marta Coscia, Giuseppe Rossi, Jose Angel Hernandez-Rivas, Carsten Utoft Niemann, Alessandro Rambaldi, Amit Shrestha, Roberto Marasca, Rosa Ruchlemer, Marzia Varettoni, Dominique Bron, Juan Marquet, Eva Gimeno, Viola Maria Popov, Massimo Gentile, Mohamed A. Yassin, Kostas Stamatopoulos, Lorenzo De Paoli, Thomas Chatzikonstantinou, Giulia Quaresmini, Luca Laurenti, Lucia Farina, Arnon P. Kater, Nimish Shah, Elisabeth Vandenberghe, José A. García-Marco, Oana Stanca, Giovanni Del Poeta, Martin Simkovic, Yervand K Hakobyan, Enrico Lista, Michael Doubek, Gilad Itchaki, Talha Munir, Paolo Ghia, Ewa Wasik-Szczepanek, Gianluigi Reda, Francesca Maria Quaglia, Maria Dimou, Gábor Barna, Lorella Orsucci, Gian Matteo Rigolin, Scarfo', L., Chatzikonstantinou, T., Rigolin, G. M., Quaresmini, G., Motta, M., Vitale, C., Garcia-Marco, J. A., Hernandez-Rivas, J. A., Miras, F., Baile, M., Marquet, J., Niemann, C. U., Reda, G., Munir, T., Gimeno, E., Marchetti, M., Quaglia, F. M., Varettoni, M., Delgado, J., Iyengar, S., Janssens, A., Marasca, R., Ferrari, A., Cuellar-Garcia, C., Itchaki, G., Spacek, M., De Paoli, L., Laurenti, L., Levin, M. -D., Lista, E., Mauro, F. R., Simkovic, M., Van Der Spek, E., Vandenberghe, E., Trentin, L., Wasik-Szczepanek, E., Ruchlemer, R., Bron, D., De Paolis, M. R., Del Poeta, G., Farina, L., Foglietta, M., Gentile, M., Herishanu, Y., Herold, T., Jaksic, O., Kater, A. P., Kersting, S., Malerba, L., Orsucci, L., Popov, V. M., Sportoletti, P., Yassin, M., Pocali, B., Barna, G., Chiarenza, A., dos Santos, G., Nikitin, E., Andres, M., Dimou, M., Doubek, M., Enrico, A., Hakobyan, Y., Kalashnikova, O., Ortiz Pareja, M., Papaioannou, M., Rossi, D., Shah, N., Shrestha, A., Stanca, O., Stavroyianni, N., Strugov, V., Tam, C., Zdrenghea, M., Coscia, M., Stamatopoulos, K., Rossi, G., Rambaldi, A., Montserrat, E., Foa, R., Cuneo, A., Ghia, P., Experimental Immunology, Clinical Haematology, and CCA - Cancer Treatment and Quality of Life
- Subjects
0301 basic medicine ,Male ,Chronic lymphocytic leukaemia ,Cancer Research ,Chronic Lymphocytic Leukemia, COVID-19 ,Chronic lymphocytic leukemia ,Comorbidity ,Severity of Illness Index ,chemistry.chemical_compound ,0302 clinical medicine ,Piperidines ,Obinutuzumab ,Surveys and Questionnaires ,hemic and lymphatic diseases ,80 and over ,Viral ,Chronic ,610 Medicine & health ,Immunodeficiency ,Aged, 80 and over ,Leukemia ,Mortality rate ,Age Factors ,Hematology ,Middle Aged ,Prognosis ,Lymphocytic ,Oncology ,030220 oncology & carcinogenesis ,Infectious diseases ,Female ,Coronavirus Infections ,medicine.drug ,Bendamustine ,medicine.medical_specialty ,Pneumonia, Viral ,Antineoplastic Agents ,Article ,NO ,03 medical and health sciences ,Betacoronavirus ,Internal medicine ,Severity of illness ,medicine ,Humans ,Chronic Lymphocytic Leukemia ,Pandemics ,Protein Kinase Inhibitors ,Aged ,Retrospective Studies ,SARS-CoV-2 ,Venetoclax ,business.industry ,Adenine ,B-Cell ,COVID-19 ,Odds ratio ,Pneumonia ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,Settore MED/15 - MALATTIE DEL SANGUE ,030104 developmental biology ,Pyrazoles ,Pyrimidines ,chemistry ,business - Abstract
Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79–7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.
- Published
- 2020
9. Complete remission induced by G-CSF in a patient with acute myeloid leukemia with t(8;21)(q22;q22)
- Author
-
Ettore Mariano Schiavone, Barbara Pocali, Giulia Scalia, Giuseppina Mele, Luigi Del Vecchio, Paolo Morabito, Felicetto Ferrara, Lucia Sebastio, Salvatore Palmieri, Ferrara, F, Schiavone, Em, Palmieri, S, Mele, G, Pocali, B, Scalia, G, Morabito, P, Sebastio, L, and DEL VECCHIO, Luigi
- Subjects
medicine.medical_specialty ,Chromosomes, Human, Pair 21 ,Gastroenterology ,Translocation, Genetic ,Immunophenotyping ,Flow cytometry ,Bone Marrow ,Internal medicine ,Granulocyte Colony-Stimulating Factor ,Humans ,Medicine ,Salvage Therapy ,medicine.diagnostic_test ,business.industry ,Auer rod ,Remission Induction ,Complete remission ,Myeloid leukemia ,Hematology ,Middle Aged ,Flow Cytometry ,Minimal residual disease ,Peripheral blood ,Treatment Outcome ,Molecular Diagnostic Techniques ,Leukemia, Myeloid ,Concomitant ,Acute Disease ,Immunology ,Female ,T(8 ,21)(q22 ,q22) ,business ,Chromosomes, Human, Pair 8 - Abstract
We describe a case of acute myeloid leukemia (AML) with t(8;21) in which complete remission (CR) was obtained with G-CSF given at 10 microg/kg in the absence of concomitant cytotoxic chemotherapy. CR was achieved following 2 weeks of therapy and confirmed by investigating minimal residual disease by four-color flow cytometry analysis. During treatment with G-CSF, maturing cells with cytoplasmic Auer Rods were observed in the peripheral blood, suggesting a differentiation effect. This case adds further evidence for a specific role of G-CSF in the treatment of AML with t(8;21), namely in patients who are not eligible for aggressive chemotherapy.
- Published
- 2003
10. Macroamylasemia in a patient with multiple myeloma
- Author
-
Gaetano Romano, A. Tirelli, Roberto Guariglia, Salvatore Guastafierro, Barbara Pocali, Marco Sagristani, Mafalda De Rienzo, Sagristani, M, Guariglia, R, Pocali, B, DE RIENZO, M, Guastafierro, Salvatore, Romano, G, and Tirelli, Armando
- Subjects
Male ,Cancer Research ,Pathology ,medicine.medical_specialty ,biology ,business.industry ,Hematology ,Disease ,Macroamylasemia ,Middle Aged ,medicine.disease ,Oncology ,Rare case ,Amylases ,biology.protein ,Medicine ,Hyperamylasemia ,Humans ,Antibody ,business ,Multiple Myeloma ,Multiple myeloma - Abstract
We report a rare case of a patient with multiple myeloma who developed hyperamylasemia not associated to hyperamylasuria and without symptoms of pancreatic or salivary disease. This condition suggested the occurrence of macroamylasemia, consisting of macromolecules of amylase bound with immunoglobulins, which are not filtered by the kidneys. Hyperamylasemia was not present at the diagnosis of myeloma and appeared at the relapse of the disease, simultaneously with the appearance of an additional gamma-chain oligoclonal component, suggesting a possible role of these chains in producing macroamylasemia. To our knowledge, this is the first report of macroamylasemia in a patient with multiple myeloma.
- Published
- 2002
11. The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.
- Author
-
Visentin A, Chatzikonstantinou T, Scarfò L, Kapetanakis A, Demosthenous C, Karakatsoulis G, Minga E, Chamou D, Allsup D, Cabrero AA, Andres M, Antic D, Baile M, Baliakas P, Besikli-Dimou S, Bron D, Chatzileontiadou S, Cordoba R, Correa JG, Cuéllar-García C, De Paoli L, De Paolis MR, Delgado J, Dimou M, Donaldson D, Catherwood M, Doubek M, Efstathopoulou M, Eichhorst B, Elashwah S, Enrico A, Espinet B, Farina L, Ferrari A, Foglietta M, Frederiksen H, Fürstenau M, García-Marco JA, García-Serra R, Collado R, Gentile M, Gimeno E, Glenthøj A, da Silva MG, Hakobyan YK, Herishanu Y, Hernández-Rivas JÁ, Herold T, Innocenti I, Itchaki G, Jaksic O, Janssens A, Kalashnikova ОB, Kalicińska E, Kater AP, Kersting S, Labrador J, Lad D, Laurenti L, Levin MD, Lista E, Lopez-Garcia A, Malerba L, Marasca R, Marchetti M, Marquet J, Mattsson M, Mauro FR, Morawska M, Motta M, Munir T, Murru R, Niemann CU, Rodrigues RN, Olivieri J, Orsucci L, Papaioannou M, Pavlovsky MA, Piskunova I, Popov VM, Quaglia FM, Quaresmini G, Qvist K, Rigolin GM, Ruchlemer R, Šimkovič M, Špaček M, Sportoletti P, Stanca O, Tadmor T, Capasso A, Del Poeta G, Gutwein O, Karlsson LK, Milosevic I, Mirás F, Reda G, Saghumyan G, Shrestha A, Te Raa D, Tonino SH, Van Der Spek E, van Gelder M, van Kampen R, Wasik-Szczepanek E, Wróbel T, Segundo LYS, Yassin M, Pocali B, Vandenberghe E, Iyengar S, Varettoni M, Vitale C, Coscia M, Rambaldi A, Montserrat E, Cuneo A, Stavroyianni N, Trentin L, Stamatopoulos K, and Ghia P
- Subjects
- Humans, SARS-CoV-2, Post-Acute COVID-19 Syndrome, Retrospective Studies, COVID-19, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
- Abstract
In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high-count monoclonal B lymphocytosis) infected by SARS-CoV-2, including the development of post-COVID condition. Data from 1540 patients with CLL infected by SARS-CoV-2 from January 2020 to May 2022 were included in the analysis and assigned to four phases based on cases disposition and SARS-CoV-2 variants emergence. Post-COVID condition was defined according to the WHO criteria. Patients infected during the most recent phases of the pandemic, though carrying a higher comorbidity burden, were less often hospitalized, rarely needed intensive care unit admission, or died compared to patients infected during the initial phases. The 4-month overall survival (OS) improved through the phases, from 68% to 83%, p = .0015. Age, comorbidity, CLL-directed treatment, but not vaccination status, emerged as risk factors for mortality. Among survivors, 6.65% patients had a reinfection, usually milder than the initial one, and 16.5% developed post-COVID condition. The latter was characterized by fatigue, dyspnea, lasting cough, and impaired concentration. Infection severity was the only risk factor for developing post-COVID. The median time to resolution of the post-COVID condition was 4.7 months. OS in patients with CLL improved during the different phases of the pandemic, likely due to the improvement of prophylactic and therapeutic measures against SARS-CoV-2 as well as the emergence of milder variants. However, mortality remained relevant and a significant number of patients developed post-COVID conditions, warranting further investigations., (© 2023 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
12. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.
- Author
-
Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, Garcia-Marco JA, Hernández-Rivas JÁ, Mirás F, Baile M, Marquet J, Niemann CU, Reda G, Munir T, Gimeno E, Marchetti M, Quaglia FM, Varettoni M, Delgado J, Iyengar S, Janssens A, Marasca R, Ferrari A, Cuéllar-García C, Itchaki G, Špaček M, De Paoli L, Laurenti L, Levin MD, Lista E, Mauro FR, Šimkovič M, Van Der Spek E, Vandenberghe E, Trentin L, Wasik-Szczepanek E, Ruchlemer R, Bron D, De Paolis MR, Del Poeta G, Farina L, Foglietta M, Gentile M, Herishanu Y, Herold T, Jaksic O, Kater AP, Kersting S, Malerba L, Orsucci L, Popov VM, Sportoletti P, Yassin M, Pocali B, Barna G, Chiarenza A, Dos Santos G, Nikitin E, Andres M, Dimou M, Doubek M, Enrico A, Hakobyan Y, Kalashnikova O, Ortiz Pareja M, Papaioannou M, Rossi D, Shah N, Shrestha A, Stanca O, Stavroyianni N, Strugov V, Tam C, Zdrenghea M, Coscia M, Stamatopoulos K, Rossi G, Rambaldi A, Montserrat E, Foà R, Cuneo A, and Ghia P
- Subjects
- Adenine analogs & derivatives, Age Factors, Aged, Aged, 80 and over, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, COVID-19, Comorbidity, Coronavirus Infections diagnosis, Coronavirus Infections mortality, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Male, Middle Aged, Pandemics, Piperidines, Pneumonia, Viral diagnosis, Pneumonia, Viral mortality, Prognosis, Protein Kinase Inhibitors pharmacology, Protein Kinase Inhibitors therapeutic use, Pyrazoles pharmacology, Pyrazoles therapeutic use, Pyrimidines pharmacology, Pyrimidines therapeutic use, Retrospective Studies, SARS-CoV-2, Severity of Illness Index, Surveys and Questionnaires, Betacoronavirus, Coronavirus Infections pathology, Leukemia, Lymphocytic, Chronic, B-Cell complications, Pneumonia, Viral pathology
- Abstract
Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79-7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.
- Published
- 2020
- Full Text
- View/download PDF
13. Vinorelbine plus intermediate dose cyclophosphamide is an effective and safe regimen for the mobilization of peripheral blood stem cells in patients with multiple myeloma.
- Author
-
Annunziata M, Celentano M, Pocali B, D'Amico MR, Palmieri S, Viola A, Copia C, Falco C, Del Vecchio L, and Ferrara F
- Subjects
- Adult, Aged, Antigens, CD34 metabolism, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cyclophosphamide administration & dosage, Cyclophosphamide adverse effects, Female, Fever chemically induced, Granulocyte Colony-Stimulating Factor administration & dosage, Hematopoietic Stem Cells drug effects, Humans, Male, Middle Aged, Multiple Myeloma blood, Multiple Myeloma pathology, Neutropenia chemically induced, Peripheral Blood Stem Cell Transplantation, Prospective Studies, Survival Analysis, Thrombocytopenia chemically induced, Transplantation, Autologous, Treatment Outcome, Vinblastine administration & dosage, Vinblastine adverse effects, Vinblastine analogs & derivatives, Vinorelbine, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Hematopoietic Stem Cell Mobilization, Hematopoietic Stem Cells cytology, Multiple Myeloma therapy
- Abstract
High dose cyclophosphamide (HD-Cy) is commonly used to mobilize stem cells in multiple myeloma (MM). However, timing of collection is variable and incidence of side effects is substantial. We evaluated a combination of vinorelbine (VNB) (25 mg/m(2) day 1) plus Cy (1.5 g/m(2) day 2) and G-CSF as mobilizing regimen in 37 patients with MM. Results were compared to those achieved in 41 previously diagnosed patients mobilized with Cy at 4 g/m(2). Overall, 36/37 patients receiving VNB-Cy (97%) mobilized, as opposed to 40/41 (97%) in the controls (p:0.51). Median CD34+ cells peak was 94/mul for VNB-Cy patients and 96 for controls, p=0.36; median number of CD34+ cells collected was 9.2x10(6)/kg and 8.7x10(6)/kg, respectively (p=0.85). Median number of days to the highest CD34 count was shorter for VNB-Cy patients (nine vs 11, p=0.001). No VNB-Cy patient experienced grade 3-4 neutropenia and thrombocytopenia, as opposed to 63 and 19% in the controls (p=0.001 and 0.01, respectively). Hospitalization from toxicity was never required in VNB-Cy patients as compared to 19% in control group (p=0.01). We conclude that an outpatient combination of VNB plus intermediate dose Cy plus G-CSF is a safe, predictable, and highly effective mobilization regimen for patients with newly-diagnosed MM.
- Published
- 2006
- Full Text
- View/download PDF
14. Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia.
- Author
-
Ferrara F, D'Arco AM, De Simone M, Mele G, Califano C, Pocali B, Danise P, and Palmieri S
- Subjects
- Aged, Aged, 80 and over, Antigens, CD34 biosynthesis, Disease-Free Survival, Female, Humans, Male, Middle Aged, Myelodysplastic Syndromes complications, Stem Cell Transplantation, Treatment Outcome, Vidarabine administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cytarabine administration & dosage, Leukemia, Myeloid, Acute drug therapy, Vidarabine analogs & derivatives
- Abstract
Background and Objectives: A phase II study was conducted to investigate the effects of a therapeutic program based on the combination of fludarabine and cytarabine (ARA-C) administered as a sequential continuous infusion in untreated elderly patients with acute myeloid leukemia (AML)., Design and Methods: Sixty-three patients with non-M3 AML, median age 69 years (range 61-81), were accrued. Twenty-four patients (38%) had AML secondary to myelodysplastic syndrome. Fludarabine and ARA-C were administered as a continuous sequential infusion for 72 and 96 hours, respectively, after a loading dose. Patients achieving complete remission (CR) were intended to receive an additional course, followed by autologous stem cell transplantation (ASCT)., Results: Overall, 42 patients (67%) achieved CR. There were 10 induction deaths (16%), while 11 patients were refractory (17%). Among those achieving a remission, 35 patients (83%) received the planned consolidation course and 29 underwent mobilization of CD34+ cells into the peripheral blood for collection, which was successful in 23 (79%). Overall, 17 patients (27% of the whole population) received ASCT. The median overall and disease-free survival were both 10 months., Interpretation and Conclusions: Patients with an intermediate karyotype and those receiving ASCT had a significantly better clinical outcome. Results in terms of CR achievement, CD34+ cell collection and ASCT feasibility. A longer follow up is needed in order to evaluate the actual benefit on long-term survival.
- Published
- 2005
15. High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia.
- Author
-
Ferrara F, Palmieri S, De Simone M, Sagristani M, Viola A, Pocali B, Fasanaro A, and Mele G
- Subjects
- Acute Disease, Adolescent, Adult, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Leukemia, Myeloid immunology, Leukemia, Myeloid mortality, Male, Middle Aged, Survival Analysis, Transplantation, Autologous, Busulfan therapeutic use, Idarubicin therapeutic use, Immunosuppressive Agents therapeutic use, Leukemia, Myeloid surgery, Stem Cell Transplantation, Transplantation Conditioning methods
- Abstract
Between 30 and 50% of patients with acute myeloid leukaemia (AML) relapse after autologous stem cell transplantation (ASCT). One possibility of reducing the relapse rate could be the adoption of conditioning regimens specifically designed for AML. We report treatment results achieved with a new conditioning for ASCT, based on high-dose idarubicin (IDA) plus oral busulphan. Patients (n = 40) were conditioned with a regimen consisting of 3 d continuous intravenous infusion IDA at 20 mg/m2, followed by 4 d conventional dose oral busulphan. Unpurged peripheral blood stem cells were used in all cases. All patients had non-M3-AML and were in first complete remission (CR). The median number of CD34+ cells infused was 6.9 x 10(6)/l (2.6-24). No case of transplant-related mortality occurred. In all cases, left ventricular ejection fraction remained unmodified after ASCT. Thirty-three of 40 patients (82%) had grade 3-4 mucositis requiring total parenteral nutrition in all cases. After a median follow up for surviving patients of 32 months from ASCT, 30 patients (75%) are alive and 26 (65%) are in continuous CR. Our data show that a conditioning regimen based on high-dose IDA plus busulphan results in an encouraging reduction of the relapse rate after ASCT in AML.
- Published
- 2005
- Full Text
- View/download PDF
16. Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilization therapy for refractory or early relapsing patients with aggressive non-Hodgkin's lymphoma.
- Author
-
Pocali B, De Simone M, Annunziata M, Palmieri S, D'Amico MR, Copia C, Viola A, Mele G, Schiavone EM, and Ferrara F
- Subjects
- Adult, Aged, Disease-Free Survival, Female, Humans, Lymphoma, Large B-Cell, Diffuse therapy, Male, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Remission Induction, Transplantation, Autologous, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Epirubicin therapeutic use, Etoposide therapeutic use, Hematopoietic Stem Cell Mobilization, Hematopoietic Stem Cell Transplantation, Ifosfamide therapeutic use, Lymphoma, Non-Hodgkin therapy, Salvage Therapy
- Abstract
The prognosis of early relapsing or refractory aggressive non-Hodgkin's lymphoma (NHL) is still poor. Effective salvage therapy should be able to induce high response rate as well as to mobilize hematopoietic precursors. A combination of ifosfamide, epirubicin and etoposide (IEV) was given to 28 patients with refractory or relapsing high grade NHL (4 lymphoblastic lymphoma and 24 large cell lymphoma). All patients were evaluated for response. After 2 courses of IEV, the overall and complete response rate were 64% and 39%, respectively. All patients were controlled for mobilization of peripheral blood stem cells, which was successful in 26 out of 28 (93%). Overall, 25 out of 26 patients proceeded to autologous stem cell transplantation (ASCT). Toxicity was mild, with no occurrence of severe persisting extra-hematologic side-effects. Following the entire therapeutic program, including IEV and ASCT, median progression free survival has not yet been reached and 21 patients are alive (18 in continuous complete remission) after a median follow-up of 18 months. Our results demonstrate that treatment with IEV regimen is effective in refractory or relapsing aggressive NHL, resulting in a high percentage of successful stem cell mobilization and feasibility of ASCT.
- Published
- 2004
- Full Text
- View/download PDF
17. Late relapse of acute promyelocytic leukemia treated with all- trans retinoic acid and chemotherapy: report of two cases.
- Author
-
Ferrara F, Selleri C, Mele G, Serio B, Palmieri S, Pocali B, Pane F, and Rotoli B
- Subjects
- Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Humans, Idarubicin administration & dosage, Male, Recurrence, Remission Induction, Salvage Therapy, Time Factors, Tretinoin administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Leukemia, Promyelocytic, Acute drug therapy
- Abstract
Two patients with acute promyelocytic leukemia (APL) relapsed at 111 and 84 months after achievement of complete remission (CR) induced by a combination of all- trans retinoic acid and chemotherapy. In both patients molecular remission, obtained after consolidation, had been confirmed at 60 months from CR achievement. At relapse, morphological, immunophenotypic, cytogenetic, and molecular analyses showed findings identical to those at diagnosis. Hematological and molecular remission was induced with the identical treatment applied at diagnosis. We conclude that, although infrequently, patients with APL treated with modern combination therapy can experience very late relapse and can be rescued with treatment similar to that administered at diagnosis.
- Published
- 2004
- Full Text
- View/download PDF
18. Prolonged molecular remission after autologous stem cell transplantation in relapsed acute promyelocytic leukemia.
- Author
-
Ferrara F, Palmieri S, Annunziata M, Pocali B, Viola A, and Pane F
- Subjects
- Adolescent, Adult, Aged, Female, Humans, Male, Recurrence, Remission Induction, Transplantation, Autologous, Leukemia, Promyelocytic, Acute therapy, Stem Cell Transplantation
- Abstract
Six patients with relapsed acute promyelocytic leukemia (APL) received autologous stem cell transplantation (ASCT) in second (n=5) or fourth (n=1) molecular remission with a molecularly negative graft. After a median follow-up of 33 months from ASCT, 5 patients are alive in molecular remission and one died 27 months after autograft from refractory relapse.
- Published
- 2004
19. Outpatient-based peripheral blood stem cell transplantation for patients with multiple myeloma.
- Author
-
Ferrara F, Palmieri S, Viola A, Copia C, Schiavone EM, De Simone M, Pocali B, D'Amico MR, Annunziata M, and Mele G
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Multiple Myeloma classification, Multiple Myeloma pathology, Neoplasm Staging, Outpatients, Stem Cell Transplantation adverse effects, Transplantation, Autologous, Treatment Outcome, Multiple Myeloma therapy, Stem Cell Transplantation methods
- Abstract
Introduction: There is a growing demand for autologous stem cell transplantation (ASCT) in newly diagnosed patients with multiple myeloma (MM), resulting in an increasing pressure on available hospital beds. In addition, more rational utilization of health resources should induce physicians to attempt therapeutic strategies aiming at reduction of costs. The aim of this study was to explore the feasibility and safety of performing ASCT on an outpatient basis, according to an early discharge method., Materials and Methods: A total of 28 patients affected by MM and in complete or partial remission were selected to receive ASCT on an outpatient basis. In particular, after conditioning with high-dose melphalan and stem cell infusion, patients were programmed to go home and to be rehospitalized in the case of febrile neutropenia or other severe toxicities., Results: All patients accepted the outpatient-based procedure. Out of 28 patients. 18 (64%) did spend the aplastic phase entirely at home following high-dose chemotherapy and stem cell infusion. A second hospital admission was required in 10 patients (36%). Febrile neutropenia and severe mucositis needing total parenteral nutrition were the most frequent causes of hospitalization. However, there were no documented infections and either fever or mucositis was easily resolved at the time of hematopoietic recovery in all patients., Conclusion: ASCT on an outpatient basis is feasible and safe in patients with MM. More than 60% of patients are manageable at home, provided that a caregiver is available.
- Published
- 2004
- Full Text
- View/download PDF
20. Therapy-related acute myeloid leukemia with t(9;11)(p12;q23) in a patient treated for acute promyelocytic leukemia.
- Author
-
Annunziata M, Palmieri S, Pocali B, De Simone M, Del Vecchio L, Vicari L, Pane F, and Ferrara F
- Subjects
- Acute Disease, Adult, Antineoplastic Combined Chemotherapy Protocols adverse effects, Chromosomes, Human, Pair 11, Chromosomes, Human, Pair 9, Female, Humans, Leukemia, Promyelocytic, Acute therapy, Neoplasms, Second Primary chemically induced, Neoplasms, Second Primary genetics, Translocation, Genetic, Tretinoin adverse effects, Leukemia, Myeloid chemically induced, Leukemia, Myeloid genetics, Leukemia, Promyelocytic, Acute complications
- Published
- 2003
- Full Text
- View/download PDF
21. Complete remission induced by G-CSF in a patient with acute myeloid leukemia with t(8;21)(q22;q22).
- Author
-
Ferrara F, Schiavone EM, Palmieri S, Mele G, Pocali B, Scalia G, Morabito P, Sebastio L, and Del Vecchio L
- Subjects
- Acute Disease, Bone Marrow pathology, Chromosomes, Human, Pair 21, Chromosomes, Human, Pair 8, Female, Flow Cytometry, Humans, Immunophenotyping, Leukemia, Myeloid diagnosis, Leukemia, Myeloid genetics, Middle Aged, Molecular Diagnostic Techniques, Remission Induction, Salvage Therapy, Translocation, Genetic, Treatment Outcome, Granulocyte Colony-Stimulating Factor therapeutic use, Leukemia, Myeloid drug therapy
- Abstract
We describe a case of acute myeloid leukemia (AML) with t(8;21) in which complete remission (CR) was obtained with G-CSF given at 10 microg/kg in the absence of concomitant cytotoxic chemotherapy. CR was achieved following 2 weeks of therapy and confirmed by investigating minimal residual disease by four-color flow cytometry analysis. During treatment with G-CSF, maturing cells with cytoplasmic Auer Rods were observed in the peripheral blood, suggesting a differentiation effect. This case adds further evidence for a specific role of G-CSF in the treatment of AML with t(8;21), namely in patients who are not eligible for aggressive chemotherapy.
- Published
- 2003
- Full Text
- View/download PDF
22. Macroamylasemia in a patient with multiple myeloma.
- Author
-
Sagristani M, Guariglia R, Pocali B, De Rienzo M, Guastafierro S, Romano G, and Tirelli A
- Subjects
- Amylases blood, Amylases urine, Humans, Male, Middle Aged, Multiple Myeloma enzymology, Hyperamylasemia etiology, Multiple Myeloma complications
- Abstract
We report a rare case of a patient with multiple myeloma who developed hyperamylasemia not associated to hyperamylasuria and without symptoms of pancreatic or salivary disease. This condition suggested the occurrence of macroamylasemia, consisting of macromolecules of amylase bound with immunoglobulins, which are not filtered by the kidneys. Hyperamylasemia was not present at the diagnosis of myeloma and appeared at the relapse of the disease, simultaneously with the appearance of an additional gamma-chain oligoclonal component, suggesting a possible role of these chains in producing macroamylasemia. To our knowledge, this is the first report of macroamylasemia in a patient with multiple myeloma.
- Published
- 2002
- Full Text
- View/download PDF
23. High-dose cytarabine as consolidation treatment for patients with acute myeloid leukemia with t(8;21).
- Author
-
Palmieri S, Sebastio L, Mele G, Annunziata M, Annunziata S, Copia C, Viola A, De Simone M, Pocali B, Schiavone EM, and Ferrara F
- Subjects
- Acute Disease, Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Leukemia, Myeloid mortality, Male, Middle Aged, Prospective Studies, Survival Analysis, Treatment Outcome, Antimetabolites, Antineoplastic administration & dosage, Chromosomes, Human, Pair 21, Chromosomes, Human, Pair 8, Cytarabine administration & dosage, Leukemia, Myeloid drug therapy, Leukemia, Myeloid genetics, Translocation, Genetic
- Abstract
Seventeen patients affected by acute myeloid leukemia (AML) with t(8;21) were prospectively programmed to receive three courses of high-dose cytarabine (HDARA-C) as post-remission therapy. The median age was 39 years and in all cases t(8;21) was the only karyotypic abnormality. Complete remission (CR) was achieved in 14 out of 17 cases (82%) and, after first consolidation with NOVIA regimen (intermediate dose ARA-C plus mitoxantrone), all patients received the three planned courses of HDARA-C (3g/m(2) q12h on days 1, 3, 5). There were two documented infections, while all patients experienced fever of unknown origin (FUO). Nonhematological toxicity was mild. Thirteen out of 14 patients are in continuous CR after a median follow-up of 44 months. One patient relapsed at 16 months and, following CR2 achievement, underwent allogeneic transplantation; he died 3 months later while in CR from acute graft versus host disease (GVHD). Survival at 5 years is projected at 79%. Our data confirm the efficacy of repeated courses of HDARAC for patients with t(8;21) AML.
- Published
- 2002
- Full Text
- View/download PDF
24. De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG).
- Author
-
Ferrara F, Palmieri S, Pocali B, Pollio F, Viola A, Annunziata S, Sebastio L, Schiavone EM, Mele G, Gianfaldoni G, and Leoni F
- Subjects
- Adult, Aged, Bone Marrow Transplantation, Cell Lineage, Combined Modality Therapy, Female, Hematopoietic Stem Cell Mobilization, Humans, Male, Middle Aged, Prognosis, Survival Analysis, Transplantation, Homologous, Vidarabine analogs & derivatives, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Cytarabine administration & dosage, Granulocyte Colony-Stimulating Factor administration & dosage, Leukemia, Myeloid pathology, Leukemia, Myeloid therapy, Vidarabine administration & dosage
- Abstract
Objectives: To evaluate therapeutic results and prognostic factors from a series of 44 patients affected by de novo acute myeloid leukemia with multilineage dysplasia (MD-AML), treated with the combination of fludarabine, cytarabine and G-CSF (FLAG)., Methods: Forty-four patients with de novo MD-AML were treated with the FLAG regimen. The median age was 61 yr (range 31-75 yr). Induction therapy consisted of the FLAG regimen; consolidation included idarubicin plus cytarabine. Patients with a compatible donor and aged less than 55 yr were programmed to receive allogeneic bone marrow transplantation (BMT), while in those without a donor and aged less than 65 yr autologous transplantation with peripheral blood stem cells mobilized by a consolidation regimen plus G-CSF was planned. Bone marrow harvest was performed in poor mobilizers., Results: Complete remission (CR) was achieved in 28 out of 44 patients (64%). Death in induction occurred in four patients (9%), while 12 patients (27%) were resistant to FLAG. Toxicity of consolidation was negligible. Most patients aged less than 60 yr and achieving CR were eligible for transplantation procedures, the main reason of exclusion being early relapse. Median overall survival and disease free survival were 16 and 22 months, respectively. Unfavorable cytogenetics was the only parameter significantly related to inferior clinical outcome following multivariate analysis., Conclusion: Multilineage dysplasia per se is not an adverse prognostic factor in AML patients treated with the FLAG regimen. Favorable results are obtained in patients with intermediate karyotype, while in those with adverse cytogenetics new approaches are clearly needed. The toxicity of the regimen is also acceptable in the elderly, and following induction/consolidation, most patients may be submitted to transplantation procedures.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.